MDT

97.5

-1.35%↓

142.16

-2.52%↓

VEEV

221.22

+1.05%↑

HQY

87.37

+0.44%↑

NEOG

9.33

-2.1%↓

MDT

97.5

-1.35%↓

142.16

-2.52%↓

VEEV

221.22

+1.05%↑

HQY

87.37

+0.44%↑

NEOG

9.33

-2.1%↓

MDT

97.5

-1.35%↓

142.16

-2.52%↓

VEEV

221.22

+1.05%↑

HQY

87.37

+0.44%↑

NEOG

9.33

-2.1%↓

MDT

97.5

-1.35%↓

142.16

-2.52%↓

VEEV

221.22

+1.05%↑

HQY

87.37

+0.44%↑

NEOG

9.33

-2.1%↓

MDT

97.5

-1.35%↓

142.16

-2.52%↓

VEEV

221.22

+1.05%↑

HQY

87.37

+0.44%↑

NEOG

9.33

-2.1%↓

Kodu・Aktsiate loetelu・Design Therapeutics Inc

Design Therapeutics Inc

Avatud

9.1 0.55

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

8.81

Max

9.62

Põhinäitajad
By Trading Economics
Sissetulek	2.1M -17M
Töötajad	55
EBITDA	4.7M -17M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+56.74% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	9. märts 2026

Turustatistika
By TradingEconomics
Turukapital	146M 520M
Eelmine avamishind	8.55
Eelmine sulgemishind	9.1

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

3.26 / 3.63 Toetus ja vastupanu

Design Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

15. jaan 2026, 18:44 UTC

Suurimad hinnamuutused turgudel

Agenus Falls After $141 Million Zydus Deal Closes

15. jaan 2026, 17:51 UTC

Suurimad hinnamuutused turgudel

Galaxy Digital Climbs on Texas Data-Center Expansion Approval, Tokenized CLO Issuance

15. jaan 2026, 17:25 UTC

Suurimad hinnamuutused turgudel

ASML Exceeds $500 Billion in Market Value on TSMC's Blockbuster Spending Plans -- Update

15. jaan 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. jaan 2026, 23:48 UTC

Market Talk

Nikkei May Decline as Enthusiasm Over Election Eases -- Market Talk

15. jaan 2026, 23:40 UTC

Market Talk

Gold Edges Lower Amid Abating Geopolitical Risks -- Market Talk

15. jaan 2026, 23:11 UTC

Market Talk

Global Equities Roundup: Market Talk

15. jaan 2026, 23:11 UTC

Market Talk

Ryman Healthcare's Resales Remain Key Concern -- Market Talk

15. jaan 2026, 23:01 UTC

Market Talk

New Zealand's Economy Enters An Upswing -- Market Talk

15. jaan 2026, 22:56 UTC

Market Talk

Tulu

Catalyst Metals Delivers a Beat With Record Gold Output -- Market Talk

15. jaan 2026, 22:51 UTC

Market Talk

James Hardie's Plant Closures Could Boost Profit by 2%-3% -- Market Talk

15. jaan 2026, 22:19 UTC

Omandamised, ülevõtmised, äriostud

Verizon Gets Final California Approval to Secure $9.6 Billion Frontier Deal -- WSJ

15. jaan 2026, 21:50 UTC

Market Talk

Tulu

Financial Services Roundup: Market Talk

15. jaan 2026, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Energy & Utilities Roundup: Market Talk

15. jaan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15. jaan 2026, 21:27 UTC

Tulu

BlackRock Caps 2025 With Record $14 Trillion in Assets -- 3rd Update

15. jaan 2026, 21:15 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Global Commodities Roundup: Market Talk

15. jaan 2026, 21:11 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Global Equities Roundup: Market Talk

15. jaan 2026, 21:11 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Canada Antitrust Watchdog Confirms Review of Canadian Energy Deal -- Market Talk

15. jaan 2026, 20:10 UTC

Market Talk

U.S. Natural Gas Futures Settle Mixed -- Market Talk

15. jaan 2026, 20:04 UTC

Tulu

These Stocks Are Today's Movers: TSMC, ASML, Goldman, Morgan Stanley, BlackRock, Coinbase, Sandisk, and More -- Barrons.com

15. jaan 2026, 20:03 UTC

Market Talk

Oil Futures Fall As Iran Risk Premium Fades -- Market Talk

15. jaan 2026, 19:26 UTC

Market Talk

Silver Closes at Fresh High -- Market Talk

15. jaan 2026, 18:29 UTC

Suurimad hinnamuutused turgudel

Agenus Falls After $141M Zydus Deal Closes

15. jaan 2026, 18:20 UTC

Tulu

Wall Street Powers Nation's Biggest Banks to Record Year -- WSJ

15. jaan 2026, 17:56 UTC

Market Talk

Tulu

U.S. Bank Results Look Encouraging for European Peers -- Market Talk

15. jaan 2026, 17:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Auto & Transport Roundup: Market Talk

15. jaan 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

15. jaan 2026, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

15. jaan 2026, 17:02 UTC

Omandamised, ülevõtmised, äriostud

KBC Group Completes Acquisition of 98.45% Stake in 365.bank From J&T Finance Group

Võrdlus sarnastega

Hinnamuutus

Design Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

56.74% tõus

12 kuu keskmine prognoos

Keskmine 15 USD 56.74%

Kõrge 18 USD

Madal 13 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Design Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Design Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

3.26 / 3.63Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bearish.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.